117 related articles for article (PubMed ID: 19195048)
1. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
Chu E; Schulman KL; Zelt S; Song X
Cancer; 2009 Apr; 115(7):1412-23. PubMed ID: 19195048
[TBL] [Abstract][Full Text] [Related]
2. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Chu E; Shi N; Wei W; Bendell JC; Cartwright T
Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine for the treatment of advanced gastric cancer.
Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
[TBL] [Abstract][Full Text] [Related]
7. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
9. Cost comparison of capecitabine in patients with breast cancer.
Rugo HS; Kohles J; Schulman KL
Am J Clin Oncol; 2010 Dec; 33(6):550-6. PubMed ID: 20051811
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
De Portu S; Mantovani LG; Ravaioli A; Tamburini E; Bollina R; Cozzi C; Grimaldi AM; Testa TE; Bianchessi C; Carteni G
J Chemother; 2010 Apr; 22(2):125-8. PubMed ID: 20435573
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
12. [Economic evaluation of capecitabine use as first line treatment in patients with advanced gastric carcinoma in Portugal].
Macedo A; Pereira C; Gonçalves J; Sousa C
Acta Med Port; 2009; 22(6):827-32. PubMed ID: 20350467
[TBL] [Abstract][Full Text] [Related]
13. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
14. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
15. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
[TBL] [Abstract][Full Text] [Related]
17. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
Lopatriello S; Amoroso D; Donati S; Alabiso O; Forti L; Fornasiero A; Smergo A; Lalli A; Iacono C; Lucenti A; D'Alonzo L; Negrini C
Eur J Cancer; 2008 Nov; 44(17):2615-22. PubMed ID: 18805000
[TBL] [Abstract][Full Text] [Related]
18. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]